150444-93-2

Basic information

• Product Name: 2-chloro-3,4-difluorobenzoic acid
• Synonyms: 2-chloro-3,4-difluorobenzoic acid
• CAS NO: 150444-93-2
• Molecular Formula: C₇H₃ClF₂O₂
• Molecular Weight: 192.5473264
• Mol File: 150444-93-2.mol

Chemical Properties

• Boiling Point: 277.9±35.0 °C(Predicted)
• Appearance: /
• Density: 1.573±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.48±0.28(Predicted)
• CAS DataBase Reference: 2-chloro-3,4-difluorobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-3,4-difluorobenzoic acid(150444-93-2)
• EPA Substance Registry System: 2-chloro-3,4-difluorobenzoic acid(150444-93-2)

Safety Data

• Hazardous Substances Data: 150444-93-2(Hazardous Substances Data)

Usage

Uses

Used in Agricultural Industry:
2-chloro-3,4-difluorobenzoic acid is used as a herbicidal agent for controlling a broad spectrum of weeds, including annual grasses and broadleaf weeds, in various crops. It functions by inhibiting the enzyme protoporphyrinogen oxidase, which plays a critical role in chlorophyll synthesis within plants. As a selective herbicide, it targets specific plants, thereby minimizing the impact on non-target species and contributing to more efficient and sustainable agricultural practices.

Upstream product

• 455-86-7 3,4-Difluorobenzoic acid 
• 67-72-1 hexachloroethane 

Downstream Products

• 1071814-19-1 N-[(2-chloro-3,4-difluorophenyl)methyl]-2-[4-methyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-5-yl]acetamide 
• 1071814-20-4 N-[(2-chloro-3,4-difluorophenyl)methyl]-2-(1,4-dimethyl-1H-pyrazol-5-yl)acetamide 
• 1001390-64-2 [(2-chloro-3,4-difluorophenyl)methyl]amine hydrochloride 
• 924626-67-5 2-chloro-3,4-difluorobenzoic acid amide 

Relevant articles and documents

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

DIHYDROPYRIMIDINE DERIVATIVES AND USES THEREOF IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES

Provided herein are dihydropyrimidine derivatives which are useful in the treatment of HBV infection or HBV-induced diseases, as well as pharmaceutical or medical applications thereof.

Novel Receptor Antagonists and Their Methods of Use

The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.

PYRAZOLE DERIVATIVES AS P2X7 MODULATORS

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: (I) wherein R1 represents C1-6 alkyl or C3-6 cycloalkyl, either of which is optionally substituted with 1, 2 or 3 ha

CYCLIC AMINE COMPOUND

A compound represented by the formula (I) or a salt thereof: (I) wherein the ring A represents a 5- to 8-membered ring which may have additional substituent besides R6, R7 and R8; R1 represents an electron-attracting group; R2, R3, R4 and R5 independently represent a hydrogen atom, a halogen atom, a group attached through a carbon atom, a group attached through a nitrogen atom, a group attached through an oxygen group, or a group attached through a sulfur atom; R6 represents a halogen atom, a group attached through a carbon atom, a group attached through a nitrogen atom, a group attached through an oxygen group, or a group attached through a sulfur atom, and R7 represents a cyano group, a nitro group, an acyl group which may have a substituent, a carboxyl group which may be esterified or amidated, or a hydrocarbon group which may have a substituent, or R6 and R7 together with a carbon atom to which they are attached may form a ring which may have a substituent; and R8 represents a hydrogen atom, a halogen atom, a group attached through a carbon atom, a group attached through an oxygen atom, or a group attached through a sulfur atom. The compound or salt has an excellent androgen receptor modulating effect, and is useful for the prevention/treatment of hypogonadism, partial androgen deficiency in aging male, decline in physical strength, cachexia, osteoporosis and the like.

Directed lithiation of unprotected benzoic acids

Benzoic acid gives the ortho-lithiated species 1 under standard conditions (s-BuLi-TMEDA-THF, -90 deg C).Reaction of 1 at -78 deg C with either methyl iodide, dimethyl disulfide, hexachloroethane, or 1,2-dibromotetrachloroethane gives the ortho-substituted product.Intramolecular competition between the carboxylic acid and methoxy, chloro, fluoro, or diethylamido functions in ortho- and -para-substituted benzoic acids establishes the carboxylic acid group to be of intermediate capacity in directing metallation.Complimentarity of directing effects is observed with the chloro and fluoro groups in the meta-substituted benzoic acid but not with the methoxy and trifluoromethyl groups.Electrophile introduction into meta- and para-lithiated benzoates occurs with equal efficacy and comparable scope.The 2,4-dihalogenobenzoic acids undergo hydrogen/metal exchange at the position flanked by both halogen substituents. 2,2-Difluoro-1,3-benzodioxole-4-carboxylic acid undergoes lithiation adjacent to the oxygen atom.By use of such methods, routes to benzoic acids contiguously tri- and tetra-substituted with a variety of functionalities have been developed.